Our Immortalized Cell Line:
WJ-iMSC hTert273
Conveyxo’s therapeutic exosomes are secreted from our proprietary hTert-immortalized Wharton’s jelly mesenchymal stem cells. This cell line combines the regenerative potency of primary MSCs with the scalability and consistency required for clinical-grade exosome manufacturing. It forms the foundation of a reliable, high-yield, and reproducible exosomes production platform built for therapeutic development.
High-Yield, Scalable Exosome Production
To ensure consistent availability, our MSCs undergo plasmid-based hTert immortalization, providing our cell line with an impressive 100-fold increase in doubling population capacity. This ensures stable and continuous production, ideal for large-scale exosome manufacturing. With cloning capacities that enable the creation of multiple Master Cell Banks, each capable of producing billions of therapeutic EV doses, we ensure an ample supply for therapeutic treatment.
Consistent Biological Potency From a Single Sourcing Strategy
Our exosomes retain strong anti-inflammatory and regenerative properties demonstrated in pre-clinical studies. Derived exclusively from umbilical cord-derived Wharton’s jelly through a single sourcing approach, our cell line offers a consistent and reliable platform for optimizing both quality and yield.
